Page last updated: 2024-11-04

vorinostat and Muscle Spasm

vorinostat has been researched along with Muscle Spasm in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"Vorinostat was well tolerated at 300 mg b."2.73Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. ( Cheson, BD; Coiffier, B; Crump, M; Frankel, SR; Jacobsen, ED; Randolph, SS; Ricker, JL; Sun, L; Xie, H, 2008)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Crump, M1
Coiffier, B1
Jacobsen, ED1
Sun, L1
Ricker, JL1
Xie, H1
Frankel, SR1
Randolph, SS1
Cheson, BD1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)[NCT00097929]Phase 218 participants (Actual)Interventional2005-05-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for vorinostat and Muscle Spasm

ArticleYear
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug

2008